Normal pressure hydrocephalus: How often does the diagnosis hold water?

Bryan T. Klassen and J. Eric Ahlskog

Neurology 2011;77;1119; Published online before print August 17, 2011;
DOI 10.1212/WNL.0b013e31822f02f5

This information is current as of March 5, 2013

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://www.neurology.org/content/77/12/1119.full.html
Normal pressure hydrocephalus
How often does the diagnosis hold water?

ABSTRACT

Objective: To determine our community’s incidence of clinically suspected normal pressure hydrocephalus (NPH), the rate of shunting for NPH, and short- and long-term outcomes of shunting.

Methods: A retrospective query of the Mayo Clinic medical records linkage system was conducted to identify residents of Olmsted County, Minnesota, undergoing an invasive diagnostic procedure for evaluation of suspected NPH from 1995 through 2003. Among patients with shunts, early- and long-term outcomes were determined via a review of available medical records.

Results: Forty-one patients underwent an invasive diagnostic procedure for evaluation of suspected NPH; 13 ultimately received shunts, representing an incidence of 1.19/100,000/year. The incidence of sustained definite improvements at 3 years after shunting was only 0.36/100,000/year. Definite gait improvement was documented in 75% at 3–6 months after shunt placement, although it dropped to 50% at 1 year and to 33% at 3 years. Only 1 of 8 patients with cognitive impairment and 1 of 6 patients with urinary incontinence had definite improvement in these symptoms at 3 years. No patient with moderate to severe postural instability experienced sustained definite improvement in any symptom. Complications occurred in 33% of patients including one perioperative death. Additional or alternative neurologic diagnoses later surfaced in 5 of 12 patients.

Conclusions: In this community, NPH is relatively rare with an incidence approximating that of progressive supranuclear palsy in this population. Whereas early gait improvement was common, only one-third of patients enjoyed continued improvement by 3 years; cognition or urinary incontinence was even less responsive long term. Baseline postural instability predicted poor outcome. Clinicians should balance potential benefits of shunting against the known risks. Neurology® 2011; 77:1119–1125

GLOSSARY

H-ICDA = International Classification of Diseases, Adapted Code for Hospitals; NPH = normal pressure hydrocephalus; OMC = Olmsted County Medical Center; PSP = progressive supranuclear palsy.

The patient presenting with gait disturbance, cognitive decline, or urinary incontinence represents a common clinical dilemma for the practicing neurologist. Although these symptoms are suggestive of normal pressure hydrocephalus (NPH), they are not specific to the diagnosis and commonly occur in neurodegenerative conditions or nonspecifically in advanced age. Ventriculomegaly, the radiologic hallmark of NPH, frequently accompanies both neurodegenerative disease and normal aging; in practice, it is difficult to determine whether ventricular enlargement results from hydrocephalus or ex vacuo change. The diagnostic uncertainty in these patients is particularly problematic, given the invasive nature of treatment for NPH. Although published guidelines generally support the role of CSF removal trials in assisting with the diagnosis, neither this nor any other test reliably assures sustained benefit from shunting. In recent years, we have noted an increase in the number of patients referred to our movement disorders practice for evaluation of possible NPH, perhaps driven partly by increased public awareness from media coverage and device manufacturer-funded advertising. It was our clinical
impression that many of these patients were ultimately not thought to have NPH, often because alternate diagnoses better explain their symptoms. This raised the question as to the true frequency of NPH and, furthermore, the short- and long-term benefit from shunting.

At Mayo Clinic in Rochester, the previously reported early experience with NPH included a generally favorable early response to shunting among appropriately selected patients. As a result, Mayo Clinic neurologists, neurosurgeons, and neuroradiologists maintain a high level of vigilance for the clinical and radiologic signs of NPH. Given our institution’s openness to this diagnosis and its position as our county’s sole neurosurgical center, we thought that the experience with NPH in our Olmsted County population should have general validity. Thus, in this community-based study, we determined the following over a 9-year period (1995–2003): 1) the incidence of clinically suspected NPH, for which the clinician was sufficiently suspicious of the diagnosis to proceed with an invasive procedure (usually lumbar CSF removal); 2) the incidence of shunting for NPH; 3) the outcomes (both short-term and long-term) among patients with shunts in Olmsted County, MN.

METHODS Standard protocol approvals, registrations, and patient consents. Our retrospective chart review was approved by the Mayo Clinic Institutional Review Board, and written informed consent for participation in research was on file for all patients included.

Study population and community referral patterns. Olmsted County, located in southeastern Minnesota, has a population of 124,277, according to the year 2000 national census. Primary healthcare services are delivered through the Mayo Clinic, affiliated clinics within Mayo Health Systems, Olmsted County Medical Center (OMC), and private providers. During the years covered by the study, neurologic consultations were only available through the Mayo Clinic Department of Neurology and through a single neurologist at OMC. The Mayo Clinic remains the county’s sole neurosurgical center, and, for this reason, the OMC neurologist chose to refer all patients with suspected NPH to the Mayo Clinic before their undergoing a high-volume lumbar puncture or other invasive diagnostic procedure.

Case definition. Cases of clinically suspected NPH were operationally defined as those in which a patient underwent an invasive diagnostic or therapeutic procedure for the evaluation or treatment of suspected NPH; this almost always included a high-volume lumbar puncture, although lumbar cisternography, continuous CSF drainage trials, or ventriculoperitoneal shunting was also allowed within our definition. At our institution, only neurologists or neurosurgeons may order these procedures, ensuring that patients falling within our definition would have been carefully screened for both NPH and competing neurologic diagnoses. Subjects with a history of congenital hydrocephalus, CNS hemorrhage, venous sinus thrombosis, CNS infection, or an obstructing lesion were excluded from analysis.

Patient ascertainment. The Mayo Clinic medical records linkage system was retrospectively queried to identify Olmsted County residents who had a clinical encounter between 1995 and 2003 designated with the International Classification of Diseases, Adapted Code for Hospitals (H-ICDA) diagnostic codes for NPH, hydrocephalus NOS, communicating hydrocephalus, or occult hydrocephalus. To assure capture of all patients in whom NPH was considered, a computerized search of the text of all clinical notes covering all county residents during this time frame was also performed using the terms normal pressure hydrocephalus or communicating hydrocephalus. The search strategy included primary care notes, allowing capture of patients primarily managed at Mayo Clinic, who had undergone surgical intervention outside the county (one such patient was, indeed, included). The ascertainment period was chosen such that all relevant clinical notes were accessible for the text-based search and adequate follow-up time was available at the time of analysis. The complete medical history of each patient identified was reviewed to determine whether a high-volume lumbar puncture or other invasive procedure was performed.

Data collection and determination of outcome. For identified cases, information collected included patient demographics, symptom duration, the presence or absence of each element of the NPH triad, the degree of postural instability, and the radiologist’s impression of neuroimaging studies. For patients undergoing shunting, early (3–6 months) and late (3 years) outcomes were retrospectively determined by a comprehensive chart review to the last available follow-up. Based on the documented impressions of the treating neurologist, the patient, and the patient’s family, outcomes were rated for each element of the clinical trial as follows: 0, no improvement beyond presurgical baseline; +, equivocal improvement; +, definite improvement but significant residual symptoms; or +++, normalization or near-normalization. In the case of a decline in patient status, the time to decline was determined using the date of the clinical assessment at which the decline was first documented. Complications of the shunting procedure were tabulated. Additional neurologic diagnoses made during follow-up were noted, as were the results of neuropsychologic examination when available.

Determination of incidence rates. Population denominators used in the calculation of incidence rates were determined by a linear interpolation of the decennial census data with a 1.9% projected growth rate after 2000. Average annual incidence rates (incidence per 100,000 person-years) were calculated for both the entire population and for the population aged 50–99 years. Because the study covered the entire target population, no sampling was involved, and, therefore, no statistical testing was applied during interpretation of the data.

RESULTS The H-ICDA database query returned 247 patients; 164 additional patients were discovered using the text-based search. From the 411 total records reviewed, 41 patients meeting the inclusion/exclusion criteria were identified; the remainder were patients with congenital or secondary hydrocephalus.
or patients in whom the treating clinician’s note explicitly dismissed NPH as a likelihood (such cases were flagged by the text-based search). All patients in whom NPH was felt to be the likely diagnosis were referred for invasive diagnostic testing. These 41 patients correspond to an incidence rate for clinically suspected NPH of 3.74/100,000/year for the total population and 15.20/100,000/year for the population older than 50 years.

Among the 41 patients with suspected NPH, all had gait disturbance, 30 had cognitive impairment, and 14 had urinary incontinence. Twenty of the 41 presented with 2 key symptoms, and 12 presented with all 3 elements of the NPH triad. Nineteen were found to have moderate to severe postural instability, defined by a positive pull test. Neuroimaging results were available for the 40 patients undergoing the invasive procedure at Mayo Clinic and, in all patients, documented ventriculomegaly.

Our practice has been to offer shunt placement only to patients with objective gait improvement after a trial of CSF removal. Of the 38 patients undergoing high-volume lumbar puncture, 14 experienced gait improvement, and 11 subsequently underwent ventriculoperitoneal shunting. Among the 3 of the 14 patients who did not undergo shunting, one had a history of carbon monoxide exposure and was later diagnosed with levodopa-responsive parkinsonism, another had a history of stroke, failed to appear for the neurosurgical evaluation, and was later diagnosed with multi-infarct dementia, and the third had a history of schizophrenia and declined neurosurgical intervention. Among the 41 patients with suspected NPH, 2 did not undergo a trial of CSF removal but underwent other invasive procedures. One underwent lumbar cisternography with results not consistent with the diagnosis; hence, this patient did not undergo shunting. The other (case 1) was taken directly for ventriculoperitoneal shunting on the basis of gait dysfunction, urinary incontinence, and imaging studies thought to be highly typical of NPH. Finally, one patient underwent ventriculoperitoneal shunting at the regional Veterans Affairs Medical Center, and outcome data for that patient were unavailable; this patient is included in the epidemiology but not outcomes sections of this study.

Of the 41 patients in whom suspicion for NPH was sufficient to justify an invasive diagnostic or therapeutic procedure, 13 (32%) ultimately underwent ventriculoperitoneal shunting (table). This corresponds to a shunted NPH incidence rate of 1.19/100,000/year for the total population and 4.82/100,000/year for those older than 50 years. The mean age at the time of shunting was 78.5 years (range 66–85 years). The gender distribution was nearly equal with 6 (46%) women and 7 (54%) men having undergone shunting. The average duration of symptoms before shunting was 2.4 years (range 0.4–7.0 years). All 13 patients undergoing shunting had gait disturbance; 8 also had cognitive dysfunction and 6 had urinary incontinence. Six patients presented with 2 of the 3 symptoms, but only 4 patients presented with all elements of the classic NPH triad. Postural instability was absent in 4 patients, mild in 3 patients, and moderate to severe in 6 patients.

Outcome data were available for all 12 patients who underwent shunting at the Mayo Clinic. At 3–6 months postprocedure, 9 of these (75%) demonstrated definite gait improvement; 2 did not respond to shunting, and 1 died in the perioperative period. By 1 year, only half (6 of 12) experienced definite gait improvement and by the 3-year endpoint only one-third (4 of 12) maintained definite improvement, whereas 5 of the original 9 responders (45%) had a decline in gait response. One of these (case 7) was found to have orthostatic myoclonus as a possible contributor to gait decline, although no new causes of gait dysfunction were present in the remaining 4. None of the 6 patients with moderate to severe postural instability experienced definite improvement in gait at the last follow-up. In cases 6, 9, and 10, the length of follow-up was less than 3 years; however, in each of these patients the benefit from shunting had already waned before the time of last follow-up, and shunt dysfunction or unrelated causes of gait dysfunction were considered and ruled out using appropriate studies. It was assumed that spontaneous improvement would not subsequently occur, and the clinical status at the last follow-up was carried forward for these 3 patients. Of the 8 patients with cognitive impairment, 4 (50%) demonstrated definite early cognitive improvement after shunting, but only 1 (13%) sustained improvement at 3 years. Similarly, of the 6 patients with urinary incontinence, 3 (50%) demonstrated definite early improvement in urinary symptoms after shunting, but only 1 (16%) sustained improvement at 3 years. If the patient who died perioperatively is removed from the denominator, favorable outcomes improve in the short term to 9 of 11 (82%) for gait and 4 of 7 (57%) for cognition and in the long term to 4 of 11 (36%) for gait and 1 of 7 (14%) for cognition. No new causes of cognitive decline or incontinence were found during life for any of the patients whose initial response to these symptoms waned.

No patient had definite improvement in cognition or urinary incontinence without concomitant definite improvement in gait at the same time point; therefore, gait outcomes were used to gauge the overall success of shunting. There was no clear relation-
### Table: Thirteen Olmstead County residents receiving shunts for NPH from 1995 to 2003

<table>
<thead>
<tr>
<th>Case</th>
<th>Age, y</th>
<th>Sex</th>
<th>Symptom duration, y</th>
<th>Baseline symptoms</th>
<th>Gait outcomes</th>
<th>Complications</th>
<th>Later diagnoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>70</td>
<td>F</td>
<td>7</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>Seizure 4 mo after shunt</td>
</tr>
<tr>
<td>2</td>
<td>75</td>
<td>F</td>
<td>4</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>Seizure 2 y after shunt</td>
</tr>
<tr>
<td>3</td>
<td>85</td>
<td>F</td>
<td>1.3</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>Pathologically confirmed progressive supranuclear palsy</td>
</tr>
<tr>
<td>4</td>
<td>76</td>
<td>M</td>
<td>2</td>
<td>±</td>
<td>+</td>
<td>+</td>
<td>Electrophysiologically confirmed orthostatic myoclonus; argyrophilic grain disease on pathology</td>
</tr>
<tr>
<td>5</td>
<td>85</td>
<td>M</td>
<td>3.4</td>
<td>+</td>
<td>+</td>
<td>0</td>
<td>Pathologic diagnosis of argyrophilic grain disease and Braak and Braak stage IV Alzheimer type changes</td>
</tr>
<tr>
<td>6</td>
<td>76</td>
<td>M</td>
<td>2</td>
<td>+</td>
<td>±</td>
<td>1.6</td>
<td>Seizure 4 mo after shunt</td>
</tr>
<tr>
<td>7</td>
<td>77</td>
<td>M</td>
<td>0.4</td>
<td>±</td>
<td>±</td>
<td>0.7</td>
<td>Seizure 2 y after shunt</td>
</tr>
<tr>
<td>8</td>
<td>82</td>
<td>F</td>
<td>1.1</td>
<td>+</td>
<td>+</td>
<td>0.9</td>
<td>Pathologically confirmed progressive supranuclear palsy</td>
</tr>
<tr>
<td>9</td>
<td>85</td>
<td>M</td>
<td>1</td>
<td>+</td>
<td>0</td>
<td>0.4</td>
<td>Traumatic subdural hematoma 1 mo after shunt</td>
</tr>
<tr>
<td>10</td>
<td>66</td>
<td>F</td>
<td>3.1</td>
<td>+</td>
<td>±</td>
<td>0</td>
<td>Clinical diagnosis of Lewy body dementia</td>
</tr>
</tbody>
</table>

**Baseline symptoms**: Gait disturbance, Cognitive decline, Urinary incontinence, Postural instability.

**Gait outcomes**: Short-term (3-6 mo), Long-term (3 y), Time to decline (y), Last follow-up (y).

**Cognitive outcomes**: Short-term, Long-term.

**Urinary incontinence outcomes**: Short-term, Long-term.

**Complications**: Seizure, Pathologic diagnosis of argyrophilic grain disease and Braak and Braak stage IV Alzheimer type changes, Electrophysiologically confirmed orthostatic myoclonus; argyrophilic grain disease on pathology, Pathologically confirmed progressive supranuclear palsy, Traumatic subdural hematoma 1 mo after shunt, Clinical diagnosis of Lewy body dementia.
<table>
<thead>
<tr>
<th>Case</th>
<th>Age, y</th>
<th>Sex</th>
<th>Symptom duration, y</th>
<th>Gait disturbance</th>
<th>Cognitive decline</th>
<th>Urinary incontinence</th>
<th>Postural instability</th>
<th>Gait outcomes</th>
<th>Length of follow-up, y</th>
<th>Time to decline, y</th>
<th>Last follow-up, y</th>
<th>Cognitive outcomes</th>
<th>Urinary incontinence outcomes</th>
<th>Complications</th>
<th>Later diagnoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>82</td>
<td>F</td>
<td>2.6</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>No decline</td>
<td>0</td>
<td>4.5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>12</td>
<td>81</td>
<td>M</td>
<td>1.2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Perioperative death</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>81</td>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Data not available</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: NPH = normal pressure hydrocephalus.

a Demographics, baseline clinical information, and postshunt outcomes are shown for the 13 Olmstead County residents undergoing ventriculoperitoneal shunting for treatment of NPH (1995–2003), organized from best to worst outcome. The duration between the first presenting symptom consistent with NPH and the time of shunt placement is shown. The degree of postural instability was assessed with the pull test: 0, normal response; ±, equivocal improvement; +, definite improvement but significant residual deficits, ++, normalization or near-normalization. Gait outcomes at the last available follow-up are similarly denoted. For patients whose gait declined after an initial improvement, the time to decline is noted.

b Three patients (cases 6, 9, and 10) had less than 3 years total follow-up and outcomes at the last available follow-up were carried forward.

c One patient (case 13) received care outside of Olmstead County, and outcome data are not available.

DISCUSSION

Although NPH is often high on the differential diagnosis for gait problems, our community-based data suggest that 1) clinical and radiologic features highly suggestive of NPH are relatively uncommon, and 2) most patients initially suspected of having NPH do not respond to a CSF removal trial. The relative low incidence of CSF overestimation in several European reports (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features. Conversely, low incidence figures have been described in several European reports (0.4%–14%). Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-
sities.4,8 Because these findings are nonspecific, relatively high prevalence figures (0.4%–14%) have been estimated when members of a population are screened for compatible clinical or neuroimaging features highly suggestive of NPH and neuroradiologic studies that simply tabulate gait disturbance demen-

Neurology 77 September 20, 2011

1123
study captured only those thought to have NPH in the context of a thorough neurologic evaluation. It is possible some residents with NPH were initially managed by non–Mayo Clinic primary providers who then referred out of county, causing our incidence rate to be falsely low. However, given our community’s high index of suspicion for this diagnosis and its usual referral patterns including residents’ ready access to neurologists, we believe our ascertainment is as ideal as possible.

In our series, initial responses to ventriculoperitoneal shunting were quite promising although usually not sustained. Objective measures were not uniformly available; thus, our study is limited by the retrospective and somewhat subjective nature of outcome determination. However, because all parties were significantly invested in the procedure and hoped for a benefit, we think it unlikely that the documented observations of the patients, family members, and treating clinicians significantly underestimate efficacy. To our knowledge, the present study represents the only community-based series in which long-term outcomes are addressed. Three- to 5-year outcomes have been reported in several referral-based series which, in keeping with our observations, generally report initial response rates greater than 70%. Some series report significant decline among initial responders, whereas others have shown that improvements are largely sustained over time. For several of these series, the loss to follow-up was substantial. Patients whose mobility deteriorates or who require placement in extended care facilities may be less able to return to their original surgical center, introducing a substantial source of bias. In contrast, we were able to assess outcomes among this subset.

Nearly half of our patients were later given an alternative neurologic diagnosis, and none of these realized sustained definite improvements after shunting. Whether they truly had NPH before developing a second neurologic disease is difficult to determine. However, it seems likely that in some, in particular the patient with pathologically proven PSP, the later-diagnosed disorder had been responsible for the entire clinical picture. All 3 patients undergoing brain autopsy had neuropathologic findings of neurodegenerative disease, consistent with observations that more than two-thirds of patients receiving shunts for NPH have one or more pathologic markers of Alzheimer disease, and those with a moderate to severe postural instability showed long-term definite improvement after shunting, and 4 of these 5 (excluding the patient who died perioperatively) were later given an additional neurologic diagnosis. Earlier reports have also suggested that imbalance is not likely to respond to CSF removal. It may be that this symptom is a hallmark of underlying neurodegenerative disease. Because postural instability is quite disabling, it is often the symptom initially prompting evaluation; our experience suggests that shunting is probably not the best course of action for these patients.

Patients and their families often perceive shunting to be a simple, safe procedure. However, it is not without risk. In our series, 1 patient experienced perioperative death and 3 more developed complications precipitated by the procedure. The one-third of our patients (4 of 12) with complications is in keeping with the 38% complication rate reported in a systematic review of prior series. Given that improvements after shunting for suspected NPH are often short-lived and given the significant potential for shunt-related complications, clinicians advising these patients need to remain mindful of the diagnostic limitations and maintain a reasonable perspective on the potential benefits of invasive CSF diversion.

AUTHOR CONTRIBUTIONS

Dr. Klassen: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, acquisition of data, and statistical analysis. Dr. Ahlskog: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, and study supervision.

DISCLOSURE

Dr. Klassen reports no disclosures. Dr. Ahlskog received the Fred Springer Award from the American Parkinson’s Disease Association; serves on the editorial boards of Parkinsonism and Related Disorders and Clinical Neuropharmacology; receives royalties from the publication of The Parkinson’s Disease Treatment Book (Oxford University Press, 2005), Parkinson’s Disease Treatment Guide for Physicians (Oxford University Press, 2009), Parkinson’s Disease and Movement Disorders (Humana Press, 2000), and Surgical Treatment of Parkinson’s Disease and Other Movement Disorders (Humana Press, 2003); and receives research support from NIH/NINDS.

REFERENCES


